Recent Updates
Recently added Catalysts
SRRK Positive Sentiment

Scholar Rock to Present at Upcoming Investor Conferences

Tuesday, November 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Scholar Rock announced its participation in upcoming investor conferences, including a fireside chat at the UBS Global Biopharma Conference. This engagement is part of the company's strategy to connect with investors and discuss its advancements in myostatin biology for treating rare neuromuscular diseases. The event is scheduled for November.

Market Sentiment Analysis

POSITIVE FACTORS

  • Scholar Rock is actively engaging with investors.
  • Participation in notable conferences enhances visibility.
  • Focus on rare neuromuscular diseases highlights commitment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+10%
120-day peak, hindsight
Typical move
6.1%
average across 12 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
SRK-181
Phase 1 · Cancer

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that management will participate in the following investor conferences: UBS Global Biopharma Conference 2026: Scholar Rock is scheduled to participate in a fireside chat at 10:00 a.m. GMT / 5:00 a.m. ET on Monday, Novem

Frequently Asked Questions

What conferences will Scholar Rock attend?

Scholar Rock will participate in the UBS Global Biopharma Conference.

When is Scholar Rock's fireside chat scheduled?

The fireside chat is scheduled for November 2026.

What is Scholar Rock's focus area?

The company focuses on rare, severe neuromuscular diseases.

What is myostatin biology?

Myostatin biology is a key area of Scholar Rock's research platform.

ShareAdd on Google
Tags: SRRK Scholar Rock investor conference biopharmaceutical neuromuscular diseases
Last updated: Nov 3, 2026

Biotech snapshot

Cash runway
$492M liquidity · $23M/mo burn
~18 mo
Low dilution risk
Lead asset
SRK-181Phase 1
Cancer →

Catalyst track record

+10%
best trade around SRRK's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for SRRK.

See every catalyst's timing & PoA →